Colorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease Analysis (Companion Faculty Lecture)

<p class="MsoNormal">Featuring a slide presentation and related discussion from Dr John Strickler, including the following topics:</p> <ul> <li>Defining molecular residual disease (MRD); tumor-informed and tumor-naïve methods for assessing (0:00)</li> <li>GALAXY and BESPOKE CRC studies of a tumor-informed MRD assay to identify patients with localized colorectal cancer who have an increased risk of recurrence and those who are likely to benefit from adjuvant chemotherapy (6:56)</li> <li>Sustained circulating tumor DNA (ctDNA) clearance and disease-free survival outcomes for patients with localized colorectal cancer (13:21)</li> <li>DYNAMIC study of a ctDNA-guided approach to adjuvant chemotherapy for patients with Stage II colorectal cancer (16:17)</li> <li>ctDNA positivity and radiographic evidence of colorectal cancer (18:48)</li> <li>ctDNA-guided approaches to escalating or de-escalating adjuvant chemotherapy for patients with localized colorectal cancer (21:24)</li> <li>Predictive r...